---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-032006"
form_type: "8-K"
ticker: null
cik: "0001711933"
company_name: "Akoya Biosciences, Inc."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T21:11:15.095645+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akoya signs $30M convertible note deal with Quanterix to fund working capital and repay debt

## Summary
- Up to $30M in convertible promissory notes to Quanterix; drawn between May 15, 2025 and merger close or July 9, 2025.
- Notes bear SOFR-based interest plus margin; interest paid monthly in cash; subordinated to existing MidCap debt.
- Conversion price tied to exchange ratio under Merger Agreement and Quanterix 10-day VWAP before deal.
- Conversion capped at 19.99% of Akoya common stock unless stockholder approval obtained.
- Registration rights agreement requires Akoya to file resale registration statement by August 13, 2025.

## SEC filing metadata
- accession: 0001104659-25-032006
- form_type: 8-K
- cik: 0001711933
- company_name: Akoya Biosciences, Inc.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711933/000110465925032006/0001104659-25-032006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711933/000110465925032006/tm2511535d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-032006
- JSON: https://secwatch.observer/filing/0001104659-25-032006.json
- Plain text: https://secwatch.observer/filing/0001104659-25-032006.txt

## Key facts
- Debt Financings
  Akoya Biosciences, Inc. incurred convertible notes of up to $30,000,000 with Quanterix Corporation at SOFR interest rate plus an applicable margin specified in the Convertible Note maturing the earliest to occur of (i) the 91st day following the earlier of (a) November 1, 2027 and (b) the date that Akoya’s indebtedness under the Credit and Security.
  - Instrument: convertible notes
  - Principal: up to $30,000,000
  - Counterparty: Quanterix Corporation
  - Rate: SOFR interest rate plus an applicable margin specified in the Convertible Note
  - Maturity: the earliest to occur of (i) the 91st day following the earlier of (a) November 1, 2027 and (b) the date that Akoya’s indebtedness under the Credit and Security
  - Event: incurrence
  source text: On April 2, 2025, Akoya Biosciences, Inc. (“Akoya”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Quanterix Corporation (“Quanterix”), pursuant to which Akoya will issue and sell to Quanterix from time to time, in a private placement, one or more convertible promissory notes having an aggregate principal amount of up to $30,000,000 (the “Convertible Notes”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711933/000110465925032006/0001104659-25-032006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.